Type 2 Inflammation: A Common Theme Amongst Several Chronic Diseases

Reynold A. Panettieri Jr., MD, explores the impact of COPD and asthma on patients' quality of life, highlighting exercise limitations and sleep disturbances.

Jonathan Silverberg, MD, PhD, MPH, examines the significant effects of chronic skin conditions such as atopic dermatitis and prurigo nodularis on patients' well-being, emphasizing the crucial role of prompt diagnosis in managing these impactful dermatologic diseases.

A key opinion leader examines the etiology of asthma and potential risk factors for COPD development, emphasizing the role of environmental exposures.

Reynold A. Panettieri Jr., MD, elaborates on the risks of lung damage resulting from exacerbations, with a focus on the role of type 2 inflammation in triggering these events.

A dermatologist explores the underlying type 2 inflammatory pathway linking atopic dermatitis and prurigo nodularis, highlighting specific biomarkers that aid in identifying patients with type 2 inflammation-driven dermatologic conditions.

A key opinion leader in dermatology explains how the presence of type 2 inflammation informs their treatment decisions for atopic dermatitis and prurigo nodularis, while also detailing additional patient-specific factors such as age, comorbidities, and disease severity that influence their therapeutic approach.

A dermatologist outlines the limitations and obstacles encountered with current therapeutic options for treating dermatologic conditions.

A key opinion leader examines how the introduction of biologic therapies revolutionized atopic dermatitis treatment, addressing strategies to manage patients' concerns about needles and injections.

An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.

A key opinion leader explores therapeutic approaches targeting inflammation to alleviate symptoms in COPD and asthma patients.

Jonathan Silverberg, MD, PhD, MPH, evaluates persistent unmet needs in the field and highlights promising new treatments currently under development.

Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.

Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and limitations in daily activities.

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.

Panelists discuss how type 2 inflammatory diseases can lead to potential long-term complications or comorbidities, including airway remodeling in asthma, nasal polyps in chronic rhinosinusitis, skin thickening in atopic dermatitis, and increased risk of cardiovascular issues and metabolic disorders.

Panelists discuss how health care providers can improve patient education and support for type 2 inflammatory conditions through personalized communication strategies and shared decision-making, while also evaluating the role of emerging biologic therapies in treatment plans based on individual patient factors, disease severity, and biomarker profiles.

Panelists discuss how unmet needs in type 2 inflammatory diseases require further research, including developing more personalized treatment approaches, identifying novel biomarkers for better disease phenotyping, improving long-term disease control strategies, and addressing the psychosocial impacts of chronic inflammatory conditions to enhance patients’ overall quality of life and outcomes.